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Dr John S. Ikonomidis (Charleston, SC).Drs Burdon and Full-
erton, I have no relationships to disclose with regard to this discus-
sion. I thank Ross Bremner and the Western Thoracic Surgical
Association for the opportunity to discuss this presentation today,
and I rise to congratulate Drs Smith and Reece and the University
of Colorado group for a really compelling characterization of this
novel and interesting spinal cord protection phenomenon that we
are really just starting to understand.
Dr Smith, I have a couple of comments and questions. I would
like you to answer each question as I give it.
First, at first glance at this data, I am astounded that 5 minutes of
normothermic ischemia caused uniformparalysis in every untreated
animal studied. This is a devastating amount of damage that cer-
tainly would not be expected to occur in a similar clinical scenario
in human beings, so I wonder whether you could comment on any
potential anatomic or vascular-related differences between the mu-
rine model and human anatomy that could impede the extrapolation
of these results to human patients into the clinical setting.
Dr Smith. Absolutely. Thank you for your kind comments. We
feel that the most important thing is that the functional injury that
we observe after aortic occlusion is very similar to what is seen
clinically in human patients. The spinal cord anatomy and vascu-
lature of a mouse is actually very similar to those of human beings,
more than other animal models that have been used. Finally, the
metabolic rate of a mouse is so much faster than that of a human
being that you might actually expect that very short ischemic times
such as those we used to have a much more pronounced effect.
Dr Ikonomidis. Thank you. Some logistic issues related to
erythropoietin. How did you arrive at the timing and dosage of
erythropoietin used in this study?
Dr Smith. We looked at the other literature, on the brain, and
there have beenmany studies of the brain that outline different tim-260 The Journal of Thoracic and Cardiovascular Surging of administration and dosing, and we chose from there. In ad-
dition, we do not know the optimal timing or dosage, and we are
doing further studies now to try to figure that out.
Dr Ikonomidis.Howmuch does this cost in a mouse, and if you
were to extrapolate that dose to human beings, how much would it
cost if we were to use this clinically?
Dr Smith. I have not broken down the cost for a mouse. If you
extrapolate the dose we used to a human dose, it would be about
120 unit/kg, so that would be about $200 to $300 per dose.
Dr Ikonomidis. It occurs to me that a single dose of erythropoi-
etin, given the timing of this study, probably would not cause sig-
nificant hematopoietic effects and is probably pretty benign. So in
light of what we know already about it, should we start doing this
in every case every time we do a descending thoracic replacement
or thoracoabdominal? What is the harm in not giving it?
Dr Smith. I think that we need to further elucidate the mecha-
nisms before we move into human trials, but because of the safety
profile of erythropoietin and in the general population much less
the aortic surgical population, I think it is very promising for treat-
ing every patient in the future.
Dr Ikonomidis. Your answer to that question is a good segue to
the next one. There is relatively little literature on this subject, but
the literature that is available shows this effect quite uniformly, so I
think that it is reasonable to say that it really exists, and I think it is
time to move forward and really start hammering out mechanisms.
Your HIF1a data were not particularly compelling, but there are
a variety of other potential mechanisms. These include anti-in-
flammatory effects, anti-apoptotic effects, modulation of oxidative
stress, neurohormonal modulation of vascular tone, and even in-
creased phosphorylation of certain upstream protective transcrip-
tion factors, such as CREB. Are you leaning toward any of these
particular mechanisms, or do you have a different mechanism in
mind? How do you plan to study that?
Dr Smith. As you mentioned, there are several possible mech-
anisms that may be responsible for this effect. Although we did not
observe a change in HIF1a at 48 hours, we still believe that it may
be responsible, so we would like to look at and are looking at dif-
ferent time points to see whether we can show different expression
after erythropoietin administration.
With respect to other mechanisms that may be involved, we are
also looking at cytokine expression as a function of time after is-
chemia and reperfusion to see whether we can determine the im-
portant proinflammatory and anti-inflammatory cytokines that
are responsible for the injury. Also, as I mentioned briefly, there
are erythropoietin derivatives that do not have any hematopoietic
effect but do have a cytoprotective effect, so we are using these
to try to tease out the actual neuroprotective effects of these drugs.
Dr Jeffrey Gaca (Durham, NC). We often do these operations
under hypothermia. Do you think that maybe you could reproduce
this experiment under hypothermia and get different results,
maybe even better results? A lot of times we don’t do them under
normothermia now.
Dr Smith. Absolutely, that is a great question. I think that if
we did these experiments under hypothermic conditions, we
might see even more neuroprotection. We do not know that for
sure, because we have only done this under normothermia, but
that would be a reasonable thing to try because that is what is
done clinically.ery c January 2011
